Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Comment by sah1on Nov 08, 2017 2:53am
383 Views
Post# 26923124

RE:RE:RE:RE:RE:RE:RE:RE:RE:Behind the mystery: Plasminogen Deficiency

RE:RE:RE:RE:RE:RE:RE:RE:RE:Behind the mystery: Plasminogen Deficiency Actually SB, I am starting to think that the plant inspection is a very big deal. I have read where FDA approval of drugs has been delayed because of issues related to manufacturing. So cGMP designation of the Laval plant will be an important milestone. With it, I am confident that Pg approval will come very quickly hopefully sometime in February.
Bullboard Posts